Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2

[1]  P. Pandolfi,et al.  Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations , 2020, bioRxiv.

[2]  Arthur S Slutsky,et al.  Human recombinant soluble ACE2 in severe COVID-19 , 2020, The Lancet Respiratory Medicine.

[3]  J. Dye,et al.  Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 , 2020, Science.

[4]  A. d’Arminio Monforte,et al.  ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population , 2020, European Journal of Human Genetics.

[5]  M. Chung,et al.  New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis , 2020, BMC Medicine.

[6]  Jinghua Lu,et al.  High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity , 2020, bioRxiv.

[7]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[8]  M. Nussenzweig,et al.  Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity , 2020, bioRxiv.

[9]  J. Witte,et al.  The landscape of host genetic factors involved in immune response to common viral infections , 2020, Genome Medicine.

[10]  Jean-Marc Rolain,et al.  ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome , 2020, Journal of Microbiology, Immunology and Infection.

[11]  Andreas R. Pfenning,et al.  Broad Host Range of SARS-CoV-2 Predicted by Comparative and Structural Analysis of ACE2 in Vertebrates , 2020, Proceedings of the National Academy of Sciences.

[12]  N. Washington,et al.  Revealing variants in SARS-CoV-2 interaction domain of ACE2 and loss of function intolerance through analysis of >200,000 exomes , 2020, bioRxiv.

[13]  Mushtaq Hussain,et al.  Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein , 2020, Journal of medical virology.

[14]  Xiaoling Liu,et al.  Imaging and clinical features of patients with 2019 novel coronavirus SARS‐CoV‐2: A systematic review and meta‐analysis , 2020, Journal of medical virology.

[15]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[16]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[17]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[18]  Chikin Chan,et al.  SARS-CoV-2 and COVID-19: The most important research questions , 2020, Cell & Bioscience.

[19]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[20]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[21]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[22]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[23]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[24]  Shibo Jiang,et al.  Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees , 2020, Nature.

[25]  Shengqing Wan,et al.  Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations , 2020, Cell Discovery.

[26]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[27]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[28]  Z. Zhao,et al.  Structure analysis of the receptor binding of 2019-nCoV , 2020, Biochemical and Biophysical Research Communications.

[29]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[30]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[31]  Shi Hu,et al.  Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig , 2020, bioRxiv.

[32]  R. Kruse.  Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China , 2020, F1000Research.

[33]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[34]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[35]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[36]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[37]  Markus S. Schröder,et al.  The Indian cobra reference genome and transcriptome enables comprehensive identification of venom toxins , 2020, Nature Genetics.

[38]  Swapan Mallick,et al.  Insights into human genetic variation and population history from 929 diverse genomes , 2019, Science.

[39]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[40]  Markus S. Schröder,et al.  The GenomeAsia 100K Project enables genetic discoveries across Asia , 2019, Nature.

[41]  K. Kinoshita,et al.  3.5KJPNv2: an allele frequency panel of 3552 Japanese individuals including the X chromosome , 2019, Human Genome Variation.

[42]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[43]  Gil McVean,et al.  Dating genomic variants and shared ancestry in population-scale sequencing data , 2018, bioRxiv.

[44]  M. Lombès,et al.  ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad , 2018, European Respiratory Journal.

[45]  O. Franco,et al.  The Rotterdam Study: 2018 update on objectives, design and main results , 2017, European Journal of Epidemiology.

[46]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[47]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[48]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[49]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[50]  N. Patterson,et al.  Estimating and interpreting FST: The impact of rare variants , 2013, Genome research.

[51]  S. Krähenbühl,et al.  Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects , 2013, Clinical Pharmacokinetics.

[52]  D. Lawlor,et al.  Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort , 2012, International journal of epidemiology.

[53]  M. Daugherty,et al.  Rules of engagement: molecular insights from host-virus arms races. , 2012, Annual review of genetics.

[54]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[55]  Sara L. Sawyer,et al.  Evidence for ACE2-Utilizing Coronaviruses (CoVs) Related to Severe Acute Respiratory Syndrome CoV in Bats , 2012, Journal of Virology.

[56]  Fang Li,et al.  Mechanisms of Host Receptor Adaptation by Severe Acute Respiratory Syndrome Coronavirus , 2012, The Journal of Biological Chemistry.

[57]  Ralph S. Baric,et al.  Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission , 2009, Journal of Virology.

[58]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[59]  Fang Li,et al.  Structural Analysis of Major Species Barriers between Humans and Palm Civets for Severe Acute Respiratory Syndrome Coronavirus Infections , 2008, Journal of Virology.

[60]  Chengsheng Zhang,et al.  Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. , 2008, The Journal of general virology.

[61]  Zhaohui S. Qin,et al.  A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.

[62]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[63]  S. Diamond,et al.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Chengsheng Zhang,et al.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.

[65]  G. Fey,et al.  Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor , 2004, Biochemical and Biophysical Research Communications.

[66]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[67]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[68]  Ylva Gavel,et al.  Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering , 1990, Protein engineering.

[69]  S WRIGHT,et al.  Genetical Structure of Populations , 1950, British medical journal.